Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone

Horvat,Matej; Zadnik,Vesna; Južnič Šetina,Tanja; Boltežar,Lučka; Pahole Goličnik,Jana; Novaković,Srdjan; Jezeršek Novaković,Barbara

doi:10.3892/ol.2018.7774

Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone

Authors:
- Matej Horvat
- Vesna Zadnik
- Tanja Južnič Šetina
- Lučka Boltežar
- Jana Pahole Goličnik
- Srdjan Novaković
- Barbara Jezeršek Novaković
View Affiliations

Affiliations: Division of Medical Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia, Department of Epidemiology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia, Department of Molecular Diagnostics, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia
Published online on: January 11, 2018 https://doi.org/10.3892/ol.2018.7774
Pages: 3602-3609
Copyright: © Horvat et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Treatment with rituximab plus a regimen of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) for patients with diffuse large B-cell lymphoma (DLBCL) has proven efficacy in clinical trials. The present study investigated its application in clinical practice. This single‑center, retrospective database analysis included patients with DLBCL treated at the Slovenian Institute of Oncology Ljubljana between 2004 and 2013. Overall survival (OS) and progression‑free survival (PFS) were assessed according to International Prognostic Index (IPI) and revised IPI (R‑IPI) categories. Overall, 573 patients with DLBCL were included in the study (median follow‑up, 45.3 months; range, 0.1‑143.0). Patients were categorized as IPI ‘low’ (n=170; 30%), ‘low‑intermediate’ (n=134; 23%), ‘high‑intermediate’ (n=129; 23%) and ‘high’ (n=140; 24%) risk. R‑IPI groups were indicated with ‘very good’ (n=59; 10%), ‘good’ (n=245; 43%) and ‘poor’ (n=269; 47%) prognosis. Ten‑year OS and PFS rates were 51 and 72%, respectively; median OS was 124 months and median PFS was not reached. Ten‑year OS rates were 80 and 87% in low‑risk and ‘very good’ prognosis groups, respectively, and 30 and 37% in high‑risk and poor prognosis patients, respectively. This analysis of patients with DLBCL indicated that many patients treated with R‑CHOP and R‑CHOP‑like regimens in the real‑world setting have excellent outcomes.

View Figures

View References

1	World Health Organization, . Diffuse large B-cell lymphoma. http://www.who.int/selection_medicines/committees/expert/20/applications/DiffuseLargeBCellLymphoma.pdf16–December. 2016
2	Li Y, Wang Y, Wang Z, Yi D and Ma S: Racial differences in three major NHL subtypes: Descriptive epidemiology. Cancer Epidemiol. 39:8–13. 2015. View Article : Google Scholar : PubMed/NCBI
3	Cancer in Slovenia 2013, . Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry. http://www.onko-i.si/fileadmin/onko/datoteke/dokumenti/RRS/LP_2013.pdf8–March. 2017
4	Cairo MS and Perkins SL: Hematological Malignancies in Children, Adolescents and Young Adults. First edition. World Scientific Publishing Co.; Singapore: 2012, View Article : Google Scholar
5	Sehn LH and Gascoyne RD: Diffuse large B-cell lymphoma: Optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 125:22–32. 2015. View Article : Google Scholar : PubMed/NCBI
6	International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar : PubMed/NCBI
7	Coiffier B, Lepage E, Brier J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
8	Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA and Horning SJ: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 24:3121–3127. 2006. View Article : Google Scholar : PubMed/NCBI
9	Pfreundschuh M, Trümper L, Österborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7:379–391. 2006. View Article : Google Scholar : PubMed/NCBI
10	Gregoric B, Zadnik V and Novakovic Jezersek B: The diffuse large B-cell lymphoma-where do we stand now in everyday clinical practice. Radiol Oncol. 46:153–159. 2012. View Article : Google Scholar : PubMed/NCBI
11	Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E and Lister TA: Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol. 32:3059–3068. 2014. View Article : Google Scholar : PubMed/NCBI
12	Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, et al: The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 109:1857–1861. 2007. View Article : Google Scholar : PubMed/NCBI
13	Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, et al: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 116:2040–2045. 2010. View Article : Google Scholar : PubMed/NCBI
14	Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, García-Marco JA, Castellví J, Montes-Moreno S, Batlle A, et al: Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Br J Haematol. 169:188–198. 2015. View Article : Google Scholar : PubMed/NCBI
15	Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, et al: Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: Results of a phase II Nordic Lymphoma Group study. Ann Oncol. 24:1385–1392. 2013. View Article : Google Scholar : PubMed/NCBI
16	Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, et al: Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: An open-label, randomised, phase 3 trial (DSHNHL 2002–1). Lancet Oncol. 13:1250–1259. 2012. View Article : Google Scholar : PubMed/NCBI
17	Fitoussi O, Belhadj K, Mounier N, Parrens M, Tilly H, Salles G, Feugier P, Ferme C, Ysebaert L, Gabarre J, et al: Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica. 96:1136–1143. 2011. View Article : Google Scholar : PubMed/NCBI
18	Tilly H, da Silva Gomes M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, et al: Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 5 Suppl 26:v116–v125. 2015. View Article : Google Scholar
19	Le Gouill S, Milpied JN, Lamy T, Delwail V, Gressin R, Guyotat D, Damaj GL, Foussard C, Cartron G, Maisonneuve H, et al: First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial. J Clin Oncol. 29 Suppl 15:S80032011. View Article : Google Scholar
20	Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, et al: Targeting B cell receptor signalling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 21:922–926. 2015. View Article : Google Scholar : PubMed/NCBI
21	Hong JY, Suh C and Kim WS: Evolution of frontline treatment of diffuse large B-cell lymphoma: A brief review and recent update. F1000Res. 5:pii: F1000 Faculty Rev-1933. 2016. View Article : Google Scholar : PubMed/NCBI
22	Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW and Smith SM: Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: Final and long-term analysis of Southwest Oncology Group Study S8736. J Clin Oncol. 34:2997–3004. 2016. View Article : Google Scholar : PubMed/NCBI
23	Olszewski AJ, Winer ES and Castillo JJ: Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the national cancer data base. Cancer Causes Control. 26:1163–1172. 2015. View Article : Google Scholar : PubMed/NCBI